NCT01943864View on ClinicalTrials.gov

A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 19, 2013

Primary Completion Date

July 1, 2014

Study Completion Date

February 1, 2016

Conditions
Cancer
Interventions
DRUG

Trametinib (single tablet)

The drug substance is blended with inert

DRUG

Trametinib (Multiple tablet)

The drug substance is blended with inert

Trial Locations (5)

277-8577

GSK Investigational Site, Chiba

537-8511

GSK Investigational Site, Osaka

411-8777

GSK Investigational Site, Shizuoka

104-0045

GSK Investigational Site, Tokyo

181-8611

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01943864 - A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers | Biotech Hunter | Biotech Hunter